| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000020961 |
| Receipt No. | R000024181 |
| Official scientific title of the study | Evaluation of diagnosis and treatment of inflammatory bowel diseases. |
| Date of disclosure of the study information | 2016/03/23 |
| Last modified on | 2017/02/21 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Evaluation of diagnosis and treatment of inflammatory bowel diseases. | |
| Title of the study (Brief title) | Evaluation of diagnosis and treatment of inflammatory bowel diseases. | |
| Region |
|
|
| Condition | ||
| Condition | Inflammatory bowel diseases | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Upper and lower gastrointestinal endoscopy, small intestine endoscopy and capsule endoscopy are essential for the diagnosis of IBD. Gastrointestinal contrast studies also become an important diagnostic tool. Findings of endoscopy and gastrointestinal contrast study, pathological findings obtained by biopsy and clinical symptoms make definitive diagnosis of IBD. In recent years, fecal occult blood test and fecal calprotectin are used as a biomarker of intestinal inflammation, which is an index of activity of the diseases.
The clinical severity of abdominal pain and diarrhea, the severity of the intestinal lesions obtained by endoscopy determine treatment of IBD patients. As a medical therapy, we can use amino salicylic acid, steroid, immunomodulator, immunosuppresant, biologics, cytapherasis, nutritional therapy and endoscopic balloon dilatation. Surgery is also chosen as surgical treatment. It is necessary to evaluate the accuracy of diagnosis and the usefulness of these therapy, and we should improve medical care of IBD patients. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | It is necessary to evaluate the accuracy of diagnosis and the usefulness of these therapy, and we should improve medical care of IBD patients. |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | IBD patients who took examinations of endoscopy and received treatment in our hospital | |||
| Key exclusion criteria | IBD patients of whom we cannot track the subsequent clinical course | |||
| Target sample size | 200 | |||
| Research contact person | |
| Name of lead principal investigator | Yoshiki Hirooka |
| Organization | Nagoya University Hospital |
| Division name | Department of Endoscopy |
| Address | 65 Tsurumai-cho, Showa-ku, Nagoya city |
| TEL | 052-744-2172 |
| hirooka@med.nagoya-u.ac.jp | |
| Public contact | |
| Name of contact person | Osamu Watanabe |
| Organization | Nagoya University Graduate School of Medicine |
| Division name | Department of Gastroenterology and Hepatology |
| Address | 65 Tsurumai-cho, Showa-ku, Nagoya city |
| TEL | 052-744-2172 |
| Homepage URL | |
| osa-wata@med.nagoya-u.ac.jp | |
| Sponsor | |
| Institute | Nagoya University Graduate School of Medicine
Department of Gastroenterology and Hepatology |
| Institute | |
| Department | |
| Funding Source | |
| Organization | no |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | No |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | observation study |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000024181 |